SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on February 20, 2003; DOI 10.1182/blood-2001-12-0290. This Article Full Text (PDF) All Versions of this Article: 2001-12-0290v1 101/12/5061    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Jaroscak, J. Articles by Kurtzberg, J. Search for Related Content PubMed PubMed Citation Articles by Jaroscak, J. Articles by Kurtzberg, J. Social Bookmarking                   What's this? Submitted December 18, 2001 Accepted February 8, 2003 Augmentation of umbilical cord blood (Ucb) transplantation with ex-vivo expanded UCB cells: results of a phase I trial using the Aastrom Replicell system Jennifer Jaroscak, Kristin Goltry, Alan Smith, Barbara Waters-Pick, Paul L Martin, Tim Driscoll, Rick Howrey, Nelson Chao, Judy Douville, Sue Burhop, Pingfu Fu, and Joanne Kurtzberg* Pediatric and Adult Bone Marrow Transplant Programs, Duke University Medical Center, Durham, NC, USA Aastrom Biosciences Inc., Ann Arbor, MI, USA * Corresponding author; email: kurtz001{at}mc.duke.edu. Allogeneic stem cell transplantation with umbilical cord blood (UCB) cells is limited by the cell dose a single unit provides recipients. Ex-vivo expansion is one strategy to increase the number of cells available for transplantation. Aastrom Biosciences Inc. developed an automated continuous perfusion culture device for expansion of hematopoietic stem cells (HSC). Cells are expanded in media supplemented with fetal bovine serum, horse serum, PIXY321, flt-3 ligand, and erythropoietin. We performed a phase I trial augmenting conventional UCB transplant with ex-vivo expanded cells. Twenty-eight patients were enrolled on the trial between 10/8/97 and 9/30/98. UCB cells were expanded in the device then administered as a boost to the conventional graft on post transplant day 12. While expansion of total cells and colony-forming units (CFU) occurred in all cases, the magnitude of expansion varied considerably. The median fold increase in nucleated cells was 2.4 (range, 1.0-8.5), in CFU-GM was 82 (range, 4.6-266.4), and in CD34+ lineage negative (lin-) was 0.5 (0.09-2.45). CD3+ cells did not expand under these conditions. Clinical scale ex-vivo expansion of UCB is feasible, and the administration of ex-vivo expanded cells is well tolerated. Augmentation of UCB transplants with ex-vivo expanded cells did not alter the time to myeloid, erythroid or platelet engraftment in 21 evaluable patients. Recipients of ex-vivo expanded cells continue to have durable engraftment with a median follow-up of 47 months (range, 41-51 ). A randomized phase II study will determine whether augmenting UCB transplants with ex-vivo expanded UCB cells is beneficial. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: G. Ghiaur, A. Lee, J. Bailey, J. A. Cancelas, Y. Zheng, and D. A. Williams Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment Blood, September 15, 2006; 108(6): 2087 - 2094. [Abstract] [Full Text] [PDF] E. A. Copelan Hematopoietic stem-cell transplantation. N. Engl. J. Med., April 27, 2006; 354(17): 1813 - 1826. [Full Text] [PDF] M. Eapen, P. Rubinstein, M.-J. Zhang, B. M. Camitta, C. Stevens, M. S. Cairo, S. M. Davies, J. J. Doyle, J. Kurtzberg, M. A. Pulsipher, et al. Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months J. Clin. Oncol., January 1, 2006; 24(1): 145 - 151. [Abstract] [Full Text] [PDF] A. C. Lipkin, P. Lenssen, and B. J. Dickson Nutrition Issues in Hematopoietic Stem Cell Transplantation: State of the Art Nutr Clin Pract, August 1, 2005; 20(4): 423 - 439. [Abstract] [Full Text] [PDF] K. K. Ballen New trends in umbilical cord blood transplantation Blood, May 15, 2005; 105(10): 3786 - 3792. [Abstract] [Full Text] [PDF] J. P. Chute, G. G. Muramoto, J. Fung, and C. Oxford Soluble factors elaborated by human brain endothelial cells induce the concomitant expansion of purified human BM CD34+CD38- cells and SCID-repopulating cells Blood, January 15, 2005; 105(2): 576 - 583. [Abstract] [Full Text] [PDF] M. J. Laughlin, M. Eapen, P. Rubinstein, J. E. Wagner, M.-J. Zhang, R. E. Champlin, C. Stevens, J. N. Barker, R. P. Gale, H. M. Lazarus, et al. Outcomes after Transplantation of Cord Blood or Bone Marrow from Unrelated Donors in Adults with Leukemia N. Engl. J. Med., November 25, 2004; 351(22): 2265 - 2275. [Abstract] [Full Text] [PDF] K. W. Christopherson II, G. Hangoc, C. R. Mantel, and H. E. Broxmeyer Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26 Science, August 13, 2004; 305(5686): 1000 - 1003. [Abstract] [Full Text] [PDF] L. Gammaitoni, K. C. Weisel, M. Gunetti, K.-D. Wu, S. Bruno, S. Pinelli, A. Bonati, M. Aglietta, M. A. S. Moore, and W. Piacibello Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication Blood, June 15, 2004; 103(12): 4440 - 4448. [Abstract] [Full Text] [PDF] D.-W. Kim, Y.-J. Chung, T.-G. Kim, Y.-L. Kim, and I.-H. Oh Cotransplantation of third-party mesenchymal stromal cells can alleviate single-donor predominance and increase engraftment from double cord transplantation Blood, March 1, 2004; 103(5): 1941 - 1948. [Abstract] [Full Text] [PDF] N. J. Chao, S. G. Emerson, and K. I. Weinberg Stem Cell Transplantation (Cord Blood Transplants) Hematology, January 1, 2004; 2004(1): 354 - 371. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020